Platelet-Activating Anti-Platelet Factor 4 Disorders

This paper explores the mechanisms and clinical implications of platelet-activating antibodies against platelet factor 4 (PF4), which lead to prothrombotic disorders such as heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombocytopenia and thrombosis (VITT). The authors aim to clarify the distinct characteristics of these disorders, including their autoimmune variants and the role of specific genetic mutations in antibody formation, while emphasizing the importance of accurate diagnostic assays and potential therapeutic strategies beyond anticoagulation.